产品
编 号：F095895
分子式：C24H24Cl2N2O2
分子量：443.37
分子式：C24H24Cl2N2O2
分子量：443.37
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 1253226-93-5
产品详情
生物活性：
AS1708727 is an orally active Foxo1 inhibitor, with EC50 values of 0.33 μM and 0.59 μM for G6Pase and PEPCK, respectively.
体内研究：
AS1708727 (30 to 300 mg/kg, orally) reduces both blood glucose and triglyceride levels, exhibiting anti-diabetic effects.Animal Model:db/db mice aged six weeks.
Dosage:100-1000 mg/kg (Pharmacokinetic Analysis).
Administration:Orally.
Result:Cmax) was 26.7 μM and maximum drug concentration time (Tmax) of 0.5 h at 300 mg/kg.Liver concentration of AS1708727 at 0.5-2 h after oral administration was 3.7- to 5.4-fold higher than the plasma concentration, indicating good liver transition of AS1708727.
Animal Model:Diabetic model mice.
Dosage:30 to 300 mg/kg.
Administration:Orally twice daily for 4 days.
Result:Blood glucose level was significantly reduced at 300 mg/kg.Plasma alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were significantly reduced at 300 mg/kg.G6Pase and PEPCK mRNA levels were significantly reduced at dosages of 100 and 300 mg/kg.
体外研究：
AS1708727 suppresses increases in blood glucose level by inhibiting gluconeogenic gene expression.
AS1708727 is an orally active Foxo1 inhibitor, with EC50 values of 0.33 μM and 0.59 μM for G6Pase and PEPCK, respectively.
体内研究：
AS1708727 (30 to 300 mg/kg, orally) reduces both blood glucose and triglyceride levels, exhibiting anti-diabetic effects.Animal Model:db/db mice aged six weeks.
Dosage:100-1000 mg/kg (Pharmacokinetic Analysis).
Administration:Orally.
Result:Cmax) was 26.7 μM and maximum drug concentration time (Tmax) of 0.5 h at 300 mg/kg.Liver concentration of AS1708727 at 0.5-2 h after oral administration was 3.7- to 5.4-fold higher than the plasma concentration, indicating good liver transition of AS1708727.
Animal Model:Diabetic model mice.
Dosage:30 to 300 mg/kg.
Administration:Orally twice daily for 4 days.
Result:Blood glucose level was significantly reduced at 300 mg/kg.Plasma alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were significantly reduced at 300 mg/kg.G6Pase and PEPCK mRNA levels were significantly reduced at dosages of 100 and 300 mg/kg.
体外研究：
AS1708727 suppresses increases in blood glucose level by inhibiting gluconeogenic gene expression.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备